Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. by Harris, Magdalena & Rhodes, Tim
Harris, M; Rhodes, T (2013) Hepatitis C treatment access and uptake
for people who inject drugs: a review mapping the role of social fac-
tors. Harm Reduct J, 10. p. 7. ISSN 1477-7517 DOI: 10.1186/1477-
7517-10-7
Downloaded from: http://researchonline.lshtm.ac.uk/1012216/
DOI: 10.1186/1477-7517-10-7
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
REVIEW Open Access
Hepatitis C treatment access and uptake for
people who inject drugs: a review mapping the
role of social factors
Magdalena Harris* and Tim Rhodes
Abstract
Background: Evidence documents successful hepatitis C virus (HCV) treatment outcomes for people who inject
drugs (PWID) and interest in HCV treatment among this population. Maximising HCV treatment for PWID can be an
effective HCV preventative measure. Yet HCV treatment among PWID remains suboptimal. This review seeks to map
social factors mediating HCV treatment access.
Method: We undertook a review of the social science and public health literature pertaining to HCV treatment for
PWID, with a focus on barriers to treatment access, uptake and completion. Medline and Scopus databases were
searched, supplemented by manual and grey literature searches. A two step search was taken, with the first step
pertaining to literature on HCV treatment for PWID and the second focusing on social structural factors. In total, 596
references were screened, with 165 articles and reports selected to inform the review.
Results: Clinical and individual level barriers to HCV treatment among PWID are well evidenced. These include
patient and provider concerns regarding co-morbidities, adherence, and side effect management. Social factors
affecting treatment access are less well evidenced. In attempting to map these, key barriers fall into the following
domains: social stigma, housing, criminalisation, health care systems, and gender. Key facilitating factors to
treatment access include: combination intervention approaches encompassing social as well as biomedical
interventions, low threshold access to opiate substitution therapy, and integrated delivery of multidisciplinary care.
Conclusion: Combination intervention approaches need to encompass social interventions in relation to housing,
stigma reduction and systemic changes in policy and health care delivery. Future research needs to better delineate
social factors affecting treatment access.
Keywords: Hepatitis C, Antiviral treatment, Treatment access, People who inject drugs, Social factors
Review
Worldwide 170 million people are estimated to live with
chronic HCV [1], with annual mortality rates due to HCV-
related liver diseases estimated at over 350 000 [2]. Global
HCV antibody prevalence among people who inject drugs
(PWID) is high. A recent systematic review, for instance,
identified 24 countries where HCV antibody prevalence in
PWID ranged from 40–60% (such as Australia, UK,
Greece), 25 countries with a range of 60-80% (USA,
Canada, Germany) and 12 (Mexico, Thailand, Russia, the
Netherlands) where prevalence was 80% or higher [3]. The
World Health Organisation identifies PWID as a key target
group for HCV prevention and treatment [2].
HCV antiviral treatment with peginterferon alfa and ri-
bavirin is the standard of care for chronic HCV, with a
50-85% cure rate depending on genotype [4]. Modelling
studies indicate that scaling-up HCV treatment access to
PWID, specifically current injectors, has the potential to
reduce the pool of communicable disease in the popula-
tion, acting as an effective preventative measure [5,6].
Qualitative [7,8] and quantitative research [9-12] shows
that PWID are interested in assessing and commencing
HCV treatment. PWID have rates of HCV treatment
adherence and successful completion comparable to
other populations [13-16]. Clinical guidelines in a number of
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countries (such as the UK, Australia, US, Canada, France)
have been modified to remove current injecting drug use as
HCV treatment exclusion criteria [17-20]. Yet HCV treat-
ment uptake among PWID is suboptimal, and estimated to
be in the order of 2-4% of those eligible [5,17,21,22]. Why
might this be so? What interplay of factors mediate HCV
treatment access for PWID? And what specifically, might be
the role of social and structural factors?
Drawing upon published literature pertaining to HCV
treatment as well as HCV among PWID, we seek to map
the social factors potentially mediating HCV treatment ac-
cess and uptake for PWID. This will assist in developing a
descriptive typology of social factors and how they func-
tion potentially as ‘barriers’ and ‘facilitators’ to treatment
access. This is necessary because there is a dearth of
pooled evidence investigating the role of social factors af-
fecting HCV treatment. We therefore draw upon previous
work on the conditionality of HIV treatment access for
PWID as a way of conceptualising ‘social factors’ and their
relevance [23-25]. This work on HIV treatment maps the
treatment access environment as a product of interplay
between macro-level factors (such as the adverse impacts
of criminalisation, social and material inequality, and
health policy) and meso-level factors (such as related to
systems of service administration, management and deliv-
ery) [26]. Given the absence of previous review on social
factors affecting HCV treatment, this review takes a two
step approach to two different literatures in an attempt to
map the field. First, we draw upon literature specific to
HCV treatment for PWID, generated through a Medline
and Scopus search of published papers since the year
2000, selected for their relevance to barriers and facilita-
tors to treatment access. Second, we draw upon literature
specific to HCV among PWID, generated through a
Medline and Scopus search of published papers since the
year 2000, and selected for their relevance regarding ‘social
factors’ linked to HCV risk, prevention or treatment. The
first of these literatures (HCV treatment) focuses predom-
inantly on clinical and individual level factors, and the sec-
ond (HCV among PWID) focuses on social and system
level factors with a heavier focus on qualitative studies.
Method
Our review comprised two steps. The first step involved
a search of the literature pertaining to HCV treatment
for PWID. The second step sought to map the role of
social factors in HCV treatment access. The searches
were conducted on Medline and Scopus databases and
limits were set for publications between 2000 and 2011
(inclusive), in English language.
Step 1
The Medline database was searched using a combina-
tion of indexed subject headings: (hepatitis C) AND
(Interferons OR treatment mp.) AND (methadone OR
Opiate Substitution Treatment OR substance abuse,
intravenous). Indexed subject headings were broadened
using the ‘explode’ operator and the addition of ‘treat-
ment’ as a key word was added. 335 articles were identi-
fied. The Scopus database search, using the combination
of keywords: (hepatitis C OR HCV) AND (interferon
OR treatment) AND (methadone OR opiate substitution
therapy OR inject* OR intravenous), yielded 77 articles.
Articles totalled 353 after removal of duplicates. A man-
ual search of article bibliographies yielded 14 records,
and seven were identified through a Google search of
the grey and policy literature. The resulting 374 docu-
ments were screened for relevance to HCV treatment
barriers and facilitators. Articles were excluded if their
primary focus was on HCV transmission, prevalence, in-
cidence, risk factors or prevention. Also excluded were
articles which focused on HCV treatment trial design
and included no outcome measures. Where multiple ar-
ticles drew on data from the same research cohort and
reported similar findings, the most relevant article was
selected. This screening process resulted in 113 articles
which were read in full and analysed for data specific to
HCV treatment barriers and facilitators (Figure 1).
The majority of the articles resulting from the first
search strategy reported on the outcomes of observa-
tional cohort studies or clinical trials (n=29), followed by
retrospective medical chart reviews (n=15) and quantita-
tive questionnaire studies (n=14). Articles primarily fo-
cused on HCV treatment management, adherence and
successful completion in PWID (n=29). Other areas
addressed included HCV treatment eligibility, access and
outcomes for people with co-morbidities (n= 13) or HIV
(n=7), rates of re-infection (n=7), integrated care (n=11),
and the knowledge and attitudes of PWID towards HCV
treatment (12). Social structural barriers to treatment ac-
cess were rarely mentioned apart from two articles
which addressed stigma [27,28], and one which
commented on geographic access to treatment [29].
Step 2
We honed the focus of our review in the second step, fo-
cusing specifically on the identification of social struc-
tural barriers to HCV treatment access for PWID.
Informed by conceptualisations of social and structural
factors and risk and enabling environments in relation
to HIV [24,25,30], Medline was searched with the fol-
lowing indexed subject headings and keywords (where
applicable): (HCV or hepatitis C) AND (substance abuse,
intravenous) AND (criminal* OR prison* OR homeless*
OR accommodation OR gender OR poverty OR social
marginalisation OR social stigma). This, with the 2000–
2011 timeframe and an English language limit, identified
182 articles. The Scopus database was searched using
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the combination of keywords (hepatitis C OR HCV)
AND (inject* OR methadone) AND (interferon OR
treatment) AND (stigma OR discrimination OR poverty
OR social marginalisation OR gender OR homeless* OR
housing OR accommodation OR criminal* OR prison*).
This, with the publication time limits of 2000 to 2011 in-
clusive, yielded 54 articles. After duplicates were re-
moved, including duplicates with search number 1, the
number of articles totalled 216. An additional six articles
were identified from a manual search of article refer-
ences, resulting in 222 articles screened with 170
excluded.
Articles were included if they contained data relating
to social structural components pertaining to HCV
treatment access. The majority of the articles resulting
from the second search strategy reported on the out-
comes of survey studies (n=16), with nine of these in-
corporating HCV antibody testing. Twelve studies were
qualitative and seven reported on the outcomes of
cohort studies. Primary areas of focus included prison
populations (n=18), homelessness (n=14), stigma (n=9),
gender (n=6) and social exclusion/poverty (n=3). Sec-
ondary analysis of all articles from both searches identi-
fied health care systems as an additional structural
barrier (Figure 2).
Results
Individual level factors
The extant literature on HCV treatment primarily focuses
on clinical and individual level factors, such as complica-
tions posed by co-morbidities, treatment side-effects, effi-
cacy and adherence, and HCV re-infection potentials.
Research capturing how HCV treatment is experienced
emphasises the potential adverse effects of treatment on
physical, psychological and social well-being. It is com-
mon, for example, for participants to describe stresses on
interpersonal relationships, compromised ability to par-
take in social, caring and work roles, as well as changes to
Figure 1 Search strategy one.
Figure 2 Search strategy two.
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mood, appearance, demeanour and self-concept after
treatment commencement [31-35]. For people considering
treatment, side-effects are a primary concern [9,17,31,
36,37], as is lengthy treatment duration and uncertain effi-
cacy [36]. For PWID who need to prioritise acute health
and social concerns over preventative health care [27,38],
who have caring responsibilities [39], and for whom the
effects of living with HCV may be relatively unproblematic
[8,37,40], there may be little incentive to commence
treatment.
Research indicates that HCV treatment fears, or disinter-
est, at the level of individual PWID can be exacerbated by:
low patient and provider treatment literacy [9,27,41-43];
fear of medical investigations, particularly involving biopsy
and phlebotomy [37,40,44,45]; concerns about potential re-
lapse to, or exacerbation of, injecting drug use [31]; com-
munication problems with providers [36,46]; and previous
stigmatising and negative experiences with health care sys-
tems and providers [27,40,45,47,48]. At the outset then, it
is clear that individual level concerns have a context, in
that they interplay with both social as well as systemic fac-
tors (such as stigma and mistrust of treatment delivery
systems).
Despite these individual level concerns, there is evi-
dence of interest in treatment uptake among PWID
[9,11]. This interest may, however, be thwarted by pro-
vider reticence to treat PWID. Provider reticence is doc-
umented as stemming from: concerns about treatment
adherence among PWID [49,50]; the impact of psychi-
atric co-morbidities [51], HIV co-infection [37,52] and/
or current alcohol and drug consumption [13,53,54]; as
well as potential HCV re-infection [55,56]; and a pre-
sumption of a lack of interest from clients [39]. A grow-
ing body of literature evidences that many of these
provider concerns should not preclude consideration for
HCV treatment, with: adherence among cohorts of
PWID equalling that of other patient groups [14,16,57];
low re-infection occurrences [55,56,58]; treatment suc-
cesses among current drug and alcohol users [13,14,16,
22,53,59-61]; as well as those with psychiatric co-
morbidities [51,62,63] and HIV [64-66]. While HCV
treatment can be complicated by HIV comorbidity, in-
cluding antiretroviral drug-drug interactions and co-
occurring antiviral toxicity [65,67,68], a 48 week treat-
ment with peginterferon plus ribavirin for all genotypes
has been found to be effective in co-infected individuals,
including for PWID [65,69].
A primary area of concern identified in the literature is
psychiatric co-morbidity among PWID, including major
depression, anxiety, posttraumatic stress and bipolar disor-
ders. PWID may engage in substance use as a form of self
medication in response [70]. Reticence to treat PWID with
psychiatric conditions is understandable, given the neuro-
psychiatric adverse effects associated with interferon
treatment, including impairment in concentration, depres-
sion, insomnia, and irritability [71,72]. Yet people with
psychiatric histories can adhere to and complete HCV
treatment at rates as high as others, if their mental health
status is closely monitored and treated [51,62,72]. This
may involve prophylactic antidepressant therapy before
beginning HCV treatment in patients thought to have a
high risk of depression [51,72]. Taken together, evidence
suggests the need for caution when commencing PWID
with psychiatric co-morbidities on HCV treatment.
Social level factors
Individual level factors affecting treatment decision mak-
ing are shaped by, as well as reproduce, the social contexts
in which efforts to access treatment are made. Treatment
access, as with patterns of health behaviour more broadly,
can therefore be seen as a product of individual and envir-
onment interactions [30]. The literature accessed in the
second step of our search points to a number of key do-
mains potentially relevant for mapping how social factors
affect HCV treatment access. These include: stigma and
discrimination; housing; geography; criminalisation; health
care systems; gender; and culture. We note the parallels
here with evidence concerning the conditionality of HIV
treatment access among PWID [24-26].
Stigma and discrimination
Stigma and discrimination are well evidenced barriers to
HCV testing and treatment access among PWID
[27,40,44,45,48,61,73]. The health care setting is reported
as the most common site of experienced HCV discrim-
ination by PWID, potentially due to the enhanced likeli-
hood or necessity of HCV status disclosure in this
environment [27,40,73,74]. Experiences of discriminatory
treatment by health care providers can be a barrier to fu-
ture health care access for PWID [38], also impacting on
HCV testing and treatment uptake [27,40,45,61]. Fears
of confidentiality breaches by health care providers in re-
lation to HCV status, and the resulting discrimination
this may provoke, have been identified as an additional
barrier to HCV testing and treatment uptake and adher-
ence [44,75] including in the prison setting [76]. Stigma
is reported to be experienced particularly acutely by fe-
male PWID [40,73,77] and can be a barrier to healthcare
seeking by PWID in rural communities who face a lim-
ited choice of health care providers [78].
HCV disclosure decisions are impacted by experiences
or expectations of stigma and discrimination [28,44,47].
Health status disclosure creates or constrains avenues
for support, especially in the context of HCV treatment
[79]. While there has been little HCV-specific research
addressing this issue, studies of HIV treatment have
shown that individuals who do not disclose their HIV
status to others in their social networks often display
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reduced levels of HIV medication adherence [80,81]. At
a macro level, stigma related to injecting drug use and
HCV can result in political inaction – with community
and government antipathy to issues affecting PWID
impacting on funds allocated to resource HCV testing,
treatment and care [82,83].
Housing
There is a clear association between homelessness and
HCV antibody positivity in countries such as UK, Canada
and USA [84-87]. Homeless PWID tend to have high sup-
port needs, yet may face additional barriers when trying to
access services [38,86]. Not having an address can, for ex-
ample, pose problems when registering for income support
or with a general practitioner, which can impact on treat-
ment access and self care more generally. While there is
scant research on the influence of accommodation circum-
stances on decisions regarding HCV treatment uptake,
homelessness and unstable housing have been identified as
barriers to uptake [17,45,61]. Unsurprisingly, PWID can be
reticent to take on a treatment with potentially significant
side effects while unstably housed [39,45,61].
HCV treatment providers generally consider home-
lessness or unstable housing to be a signifier for
unmanageability and a contraindication for treatment
consideration [14,88]. Yet, notable exceptions exist. Ser-
vices in London [60] and Vancouver [89], for example,
have successfully commenced HCV treatment with
homeless and unstably housed PWID, by providing out-
reach services to distribute treatment [60]; offering
weekly interferon injections and directly observed ther-
apy at OST prescribing services [89]; and/or providing
small fridges for people in hostels and other unstable ac-
commodation in which to store interferon [61]. Treat-
ment adherence among unstably housed PWID has been
reported favourably [60]. Taken together, the capacity of
unstably housed individuals to cope with the potential
rigors of treatment is critical to assessment, including
ascertaining the additional supports required.
Geographic access
For PWID living in rural areas, transport costs and lim-
ited choice of health care practitioners, coupled with so-
cial isolation and stigma can constitute barriers to HCV
screening and management [29,90]. Studies in France
have found that poor geographic access to primary
healthcare can have a negative influence upon HCV
screening uptake [91,92]. A similar study in Scotland
found stronger associations between socioeconomic
deprivation and limited HCV testing uptake than those
related to geographic access. Importantly, however, geo-
graphic access was found to affect people on OST more
than non-OST participants [78]. Limited geographic mo-
bility can also impact on PWID in large centres, such as
London and Sydney, who may be reticent to travel out-
side of their known area to access HCV testing and
treatment [39,60]. Money making, drug procurement,
and/or OST dosing demands as well as transport costs
and transport access create incentives for PWID not to
leave their geographic area to attend non-acute health
care appointments [27,39,45]. A Dublin based qualitative
study found that convenience was one of the most im-
portant facilitators to treatment appointment attend-
ance, with geographic distance from the hospital
discouraging attendance [40].
Criminalisation
The detrimental impact of the criminalisation of PWID
on HIV treatment access and adherence is well docu-
mented [24,25], but more speculative in relation to HCV
treatment access. Evidence more broadly suggests that
drug policies emphasising criminalisation can adversely
affect treatment access through the confiscation of med-
ications by police, reluctance among PWID to seek help,
and the interruption of treatment following arrest, de-
tention or incarceration [23,24]. Often the effects of
drug policies emphasising criminalisation may be indir-
ect in relation to HIV or HCV treatment access. For in-
stance, engagement with drug treatment, and especially
OST, can enhance HCV treatment access, uptake and
adherence among PWID [93], as it does with HIV treat-
ment [94,95], but is limited in many countries, especially
in the east of Europe, and most obviously in Russia
where it is legally prohibited.
A consequence of the criminalisation of PWID is the
risk of their incarceration. HCV is endemic in prison pop-
ulations globally [96], with recorded prevalence among in-
mates as high as 57/58% (Australia, Greece) [98]. HCV
treatment availability in prisons is uneven [90,96], with
barriers to treatment access including: limited access to
diagnostic tests, biopsy requirements and delays; abstin-
ence eligibility requirements; prohibitive costs to delivery;
and lack of infrastructure and funding [90]. In countries
where HCV treatment is available in prisons, such as the
UK, USA, Canada, France and Australia, there can be add-
itional difficulties with: taking medications into prison;
obtaining consistent clinical monitoring, medical support
and follow-up; biopsy requirements; treatment interrup-
tions due to prison transfers, intake and release; lack of
aftercare; and limited understanding of HCV treatment by
prison staff [40,77,96-99]. There are, however, docu-
mented examples of successful HCV treatment provision
in prisons, resulting in rates of viral response comparable
to treatment in the community [96,98,100].
Health care systems
The highly compartmentalised nature of health care sys-
tems can create a barrier to comprehensive care for
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PWID whose needs are complex and may span multiple
domains, such as drug dependency treatment, acute
health care (wounds and infections), psychiatry and
hepatology. Hospital-based HCV treatment is often not
ideally suited to PWID due to: geographic distance;
referral-associated delays [40]; inflexible appointment
policies; lengthy waiting times [40,45,61,99,101]; limited
infrastructure and psychosocial supports [46,90]; abstin-
ence requirements [40,45]; and prejudicial attitudes of
some staff to PWID [40,102]. Barriers to HCV treatment
access for PWID include a lack of continued engage-
ment in medical care at the same site [37,61], with some
PWID experiencing a lack of consistency in the manage-
ment and monitoring of their HCV [8], and an accom-
panying confusion about HCV symptoms, test results
and status [8,9]. Navigating health care systems and un-
familiar hospital settings can be daunting for PWID, par-
ticularly for those who may have had previous negative
experiences with providers [8,45,74].
Health systems' information sharing and confidentiality
structures (private versus open spaces, clinics with separ-
ate entrances, information sharing protocols) may also
perpetuate perceptions of stigma and negative treatment
experiences [8,40,103]. Organisational information sharing
restrictions can also pose a barrier to adequate care. For
example, a qualitative Australian study found that many
health care workers, primarily nurses, chose not to dis-
close knowledge of their HCV treatment patients’ drug
using practices to specialist physicians. This was often in
order to protect the patient, but could place additional re-
sponsibility on nurses and social workers for a patient’s
wellbeing, whilst keeping specialist physicians in the dark
about treatment successes in the context of active drug
use [104].
Communication difficulties between patients and spe-
cialists are a common finding in the HCV treatment lit-
erature. Research participants have reported feeling
unprepared for HCV treatment and experiencing more
severe and varied side-effects than they had been led to
expect by medical providers [33,34,46]. Reasons for poor
communication include: physician’s inadequate explan-
ation of treatment side-effects; use of medical jargon; in-
sufficient duration of consultation; and lack of time and
minimal attention to patient concerns [31,33,34,40,44,
46,74]. Training in providing care for, and addressing is-
sues relevant to, PWID is often lacking or only superfi-
cially provided to HCV treatment providers which may
exacerbate unrealistic expectations and communication
difficulties [72]. Pre- and post-HCV test counselling has
been identified as an area requiring skills development
[42,105], and there is a need for physicians to be respon-
sive to patients’ reports of adverse treatment effects [72].
An obstacle to communication that has received little at-
tention to date is language barriers between some
immigrants and minority ethnic groups and their HCV
treatment providers [61,106].
Gender
There is emerging evidence describing how gender medi-
ates the experience of HCV [77,107]. Women may experi-
ence stigma associated with injecting drug use and HCV
more keenly than men [28,40,77]. Whilst there is a dearth
of research investigating how gender affects HCV treat-
ment access specifically [77], studies have found women’s
concerns about confidentiality, stigma, treatment side ef-
fects and intolerance to impact on their treatment uptake
decisions more than men [40,108]. HCV treatment know-
ledge has also been found to be particularly low among
women [12,27], with women having higher HCV treat-
ment refusal and/or premature interruption rates than
men [108,109]. One study, however, reports a significantly
higher rate of dropout from pre-HCV treatment manage-
ment among men [110]. Evidence more broadly suggests
that women’s treatment access decisions are situated
alongside their caring responsibilities [27,61], lack of en-
gagement with services (including due to fear of child re-
moval [61,111,112]), incidences of physical, sexual,
emotional violence [111-113], and the demands of funding
a regular drug supply, including through sex work
[111,112]. There is a need to further investigate how gen-
der shapes barriers and facilitators to HCV treatment ac-
cess, uptake and adherence.
Culture
There is scant research exploring how culture, ethnicity
and migrant status might impact on treatment access
among PWID. Hall and colleagues [114] report that
non-white people living with HIV in San Francisco study
were less likely to undergo HCV testing and referral
than their white counterparts, even though all were in
touch with primary health care providers. They offer no
hypothesis for this finding, calling for further research to
address ethnic disparities in HCV care. Giordano et al.
[106] found lower treatment initiation rates in black eth-
nic minority individuals attending a Canadian HCV
clinic than their white counterparts, positing that this
may result from physician’s reticence to treat, based on
their knowledge of reduced SVR rates in black ethnic
populations. Almosio et al. [115] recommend that a ‘so-
cial assessment’ should be undertaken prior to commen-
cing treatment which includes noting undocumented
migrant status, sedentary or nomadic living conditions,
the possibility of relocation or return to the homeland,
and the impact of cultural understandings of illness and
death on treatment acceptability. They recommend im-
mediate treatment if the individual is likely to return to
a country of origin where antiviral drugs are not avail-
able. London-based research has found that immigrant
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PWID are often very motivated to access HCV treat-
ment, yet they and their providers face challenges related
to: language barriers; deportation possibilities; lack of
benefit access; long working hours and potential coer-
cion – especially for women – to enter into treatment
by partners and/or relatives. Recommendations include
flexible service provision to allow for inflexible work
commitments and, even when relatives and partners are
available to translate, the provision of at least one ses-
sion with a skilled interpreter to ascertain treatment
readiness [61].
Discussion
In keeping with a risk and enabling environment frame-
work, we have sought to map the key domains of social
factors affecting HCV treatment access and uptake for
PWID. Given the paucity of pooled evidence specific to
HCV treatment among PWID, we emphasise the prelim-
inary nature of this exercise. We conclude by addressing
the implications of the review for creating an enabling
environment for HCV treatment access.
HCV treatment need is socially situated
HCV treatment need is a relative concern. HCV infec-
tion and its treatment are situated inside a context of
competing everyday concerns experienced by PWID,
many of which appear more pressing [27,28]. Research
evidences how poverty, homelessness, the demands of
funding and maintaining an illicit drug dependency, fear
of arrest and incarceration, needle and syringe access,
OST provision and restrictions, managing childcare and
possible child removal, stigma and social isolation, dis-
trust of police and health care services, and the resulting
self management of acute and ongoing health concerns
(such as soft tissue infections, drug withdrawal, overdose
and depression) and interpersonal violence can all
take precedence over HCV prevention or treatment
[27,38-40,61,113].
In recognising HCV treatment need as relative, we
caution against unrealistic expectations of treatment up-
take. Initiatives to enhance treatment access and uptake
among PWID are increasingly promoted in population
terms, with modelling studies illustrating the cost effect-
ive prevention utility of HCV treatment for PWID [5].
Data demonstrating potential decreases in morbidity,
mortality and health system spending are compelling in
policy environments where treatment support and care
for PWID are generally de-prioritised. Against this im-
petus, it is important to recognise HCV treatment need
as a product of ‘situated rationality’ wherein PWID are
positioned as entitled to access any treatment available
as well as entitled to defer or refuse such treatment. A
population-based impetus to increase treatment access
and uptake among PWID may place an unwelcome onus
on already marginalised individuals to undertake treat-
ment for which they may not be ready or willing. The
promotion of universal treatment uptake (including for
prevention effect) in the absence of developing concomi-
tant social and structural interventions is a fragile and at
best medium-term strategy. This also runs the risk of
locating responsibility for low treatment uptake with
affected individuals rather than with the social institu-
tions and conditions generative of treatment access
obstacles.
HCV treatment access requires social intervention
In recognising HCV treatment access decisions as a rela-
tive concern, it becomes clear that individual-level con-
cerns are shaped by, as well as reproduced through, a
variety of social factors which interact as barriers to
accessing treatment. This means that PWID who are
both in need and eligible for treatment may be unable to
realise their treatment opportunity. We have identified
social stigma, housing, criminalisation, health care sys-
tems, and gender as key domains in the conditionality of
HCV treatment access, and thus also, as important tar-
gets for social and structural change. We lack the evi-
dence to document here how, for instance, interventions
targeting stigma reduction, stable housing, or systemic
changes to treatment delivery, may impact upon HCV
treatment access and uptake, and although having noted
above some such examples [59-61], identify these as crit-
ical to future research. Envisaging HCV treatment for
PWID as socially situated implies that access is going to
be best enhanced when treatment is designed in a com-
bination intervention approach and when delivered
through integrated multidisciplinary models.
Current operating definitions of ‘combination inter-
vention’ in harm reduction for PWID, such as those pro-
moted by the World Health Organization [116], tend to
be narrowly defined primarily around biomedical and
behavioural interventions. One specific and well
evidenced dimension of HCV treatment combination
intervention is the critical role of OST in enhancing
HCV treatment access, tolerability and adherence
[15,50,117]. It has been recommended, for example, that
small increases in methadone doses (10 – 15 mg) can
help manage HCV treatment side-effects [118], as well
as mitigate against potential relapses to – or exacerba-
tion of – injecting drug use [119]. Low threshold access
to OST also enhances the impact of HCV prevention
[120,121]. The impact of HIV treatment and prevention
interventions are similarly enhanced when delivered in
combination with high coverage OST [94,95]. The
provision of OST take-home doses has been found to
enhance PWID trust and engagement with services, as
well as proving beneficial for those experiencing HCV
treatment related side effects [45,61]. Recommendations
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for increased access to OST take-home doses
[45,61,122] are however, controversal within policy envi-
ronments favouring ‘recovery’ from illicit drugs of de-
pendance, which – in countries such as the UK –
include service incentivisation to restrict ongoing OST
provision [122]. Enhancing access to OST is a structural
intervention potentially facilitating HCV treatment ac-
cess, uptake and outcome for PWID.
We also find that HCV treatment access is also facili-
tated through a combination of low threshold treatment
access alongside the delivery of supports in relation to
adherence, treatment literacy, and social welfare. Exam-
ples of targeted access support include: HCV treatment
provision in OST services [45,60,61,93,123] and in con-
junction with GP shared care [14]; relaxed eligibility re-
quirements [14,45,60,61]; and flexible opening hours and
appointment times [45,61,124]. Targeted adherence sup-
ports include: electronic reminder systems [71]; co-
ordination with pharmacies for medication dispensing
[124]; directly observed therapy [59]; respectful client-
centred continuity of care [40,61,71]; nurse provided
interferon injections [40]; improved phlebotomy services
[45,61,124], including provision to use external jugular
venepuncture [125]; and flexible OST provision, includ-
ing access to take home doses [126]. Targeted treatment
literacy supports include: education for PWID [127], as
well as training and support for drug and alcohol staff
[128] and primary care providers, including the use of
video conferencing [129]. While less frequently docu-
mented or evaluated, evidenced targeted social supports
include: peer support groups [128,130]; peer-workers in-
tegrated into HCV treatment provision [131]; improved
psychological services [124]; and assistance with prac-
tical problems, such as transportation, accommodation
and welfare benefit access [61,72,128]. The combination
of social and structural supports facilitating HCV treat-
ment access and engagement cautions against an
overly narrow biomedical interpretation of combination
intervention.
In parallel with the need to design HCV treatment as part
of a combination intervention approach, it appears that op-
timal conditions for treatment delivery comprise integrating
care through multidisciplinary teams [14,57,61,123,124].
The delivery of HCV treatment in drug and alcohol set-
tings is an effective way of facilitating low threshold access
to HCV treatment as well as integrating treatment along-
side other forms of health and social care [15,50,60,
61,117]. Yet recent research also cautions against simply
‘adding on’ HCV treatment to drug and alcohol services
that are ill equipped to offer flexible and multi-disciplinary
care [132,133]. This research notes the potentially detri-
mental impact of HCV provision in highly regulated OST
clinics and raises concerns about the discriminatory atti-
tude of some drug treatment staff to people with HCV
[133,134]. Moreover, ‘one-stop-shop’ models of integrated
treatment can run the risk of breaching patient confidenti-
ality concerns regarding their HCV status [39], while
pharmacotherapy services which preclude disclosure of
current drug use makes using such services as a point of
low threshold access for HCV treatment difficult.
Conclusion
With the efficacy of HCV treatment for PWID well
evidenced [13,16,89], yet treatment uptake variable and
suboptimal [17,21,22], it is timely to move beyond the
evidencing of treatment impact among PWID to also
consider targeting the factors which inhibit or facilitate
treatment access and uptake. We have made a prelimin-
ary attempt to map descriptively the social factors medi-
ating HCV treatment access, but what is needed is
further research to systematically generate and pool such
evidence to determine how multiple social factors inter-
play in particular settings. A priority is to move beyond
typological description towards building models of treat-
ment access with the capacity to include environmental
factors and the scope to inform social intervention re-
sponses [135]. The study of the conditionality of HIV
treatment access among PWID has some useful parallels
[24-26]. We suggest that interventions oriented to creat-
ing opportunities for stable housing, stigma reduction
and systemic changes in policy and health care delivery
have the capacity to play a critical role in enhancing
HCV treatment access and uptake for PWID. This sug-
gests a combination intervention approach which does
not overly rely on biomedical interventions but which
includes social, welfare and structural interventions and
which seeks to integrate such care services as much as
possible at the point of delivery.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
MH carried out the literature searches, review and manuscript drafting. TR
contributed to the review design and provided critical revision of manuscript
drafts. Both authors read and approved the final manuscript.
Acknowledgements
Anthea Martin, London School of Hygiene and Tropical Medicine, for
valuable research assistance. MH is funded by the National Institute for
Health Research and Tim Rhodes by LSHTM Core funding. The World Health
Organisation for Europe, the European Commission and the National
Institute for Health Research have provided funding for research assistance
and associated qualitative research.
Received: 6 August 2012 Accepted: 13 April 2013
Published: 7 May 2013
References
1. World Health Organisation: Hepatitis C facts and figures; 2011. http://www.
euro.who.int/en/what-we-do/health-topics/diseases-and-conditions/
hepatitis/facts-and-figures/hepatitis-c.
Harris and Rhodes Harm Reduction Journal 2013, 10:7 Page 8 of 11
http://www.harmreductionjournal.com/content/10/1/7
2. World Health Organization: Resolution A63/15: Viral hepatitis. 63rd World
Health Assembly; 2010. http://apps.who.int/gb/ebwha/pdf_files/WHA63/
A63_15-en.pdf.
3. Nelson PK, et al: Global epidemiology of hepatitis B and hepatitis C in people
who inject drugs: results of systematic reviews. Lancet 2011, 378:571–583.
4. Ghany M, Strader B, Thomas D, Seeff L: Diagnosis, management and
treatment of HCV: An update. Hepatology 2009, 49:1335–1374.
5. Martin NK, et al: Can antiviral therapy for hepatitis C reduce the
prevalence of HCV among injecting drug user populations? A modeling
analysis of its prevention utility. J Hepatol 2011, 54:1137–1144.
6. Vickerman P, Hickman M, Judd A: Modelling the impact on HCV
transmission of reducing syringe sharing: London case study. Int J
Epidemiol 2007, 36:396–405.
7. Doab A, Treloar C, Dore G: Knowledge and attitudes about treatment for
hepatitis C virus infection and barriers to treatment among current
injection drug users in Australia. Clin Infect Dis 2005, 40:S313–S320.
8. Treloar C, Holt M: Drug treatment clients’ readiness for hepatitis C
treatment: implications for expanding treatment services in drug and
alcohol settings. Aust Health Rev 2008, 32:570.
9. Canfield KM, Smyth E, Batki SL: Methadone maintenance patients’
knowledge, attitudes, beliefs, and experiences concerning treatment for
hepatitis C virus infection. Subs Use Misuse 2010, 45:496–514.
10. Grebely J, et al: Barriers associated with the treatment of hepatitis C virus
infection among illicit drug users. Drug Alcohol Depend 2008, 93:141–147.
11. Strathdee SA, et al: Factors associated with interest in initiating treatment
for hepatitis C virus (HCV) infection among young HCV-infected injection
drug users. Clin Infect Dis 2005, 40:S304–S312.
12. Walley A, White M, Kushel M, Song Y, Tulsky JP: Knowledge of and interest
in hepatitis C treatment at a methadone clinic. J Subst Abuse Treatment
2005, 28:181–187.
13. Bruggmann P, et al: Active intravenous drug use during chronic hepatitis
C therapy does not reduce sustained virological response rates in
adherent patients. J Viral Hepat 2008, 15:747–752.
14. Jack K, Willott S, Manners J, Varnam MA, Thomson BJ: Clinical trial: a
primary-care-based model for the delivery of anti-viral treatment to
injecting drug users infected with hepatitis C. Aliment Pharmacol Ther
2009, 29:38–45.
15. Melin P, et al: Effectiveness of chronic hepatitis C treatment in drug users
in routine clinical practice: results of a prospective cohort study. Eur J
Gastroenterol Hepatol 2010, 22:1050–1057.
16. Sylvestre DL: Treating hepatitis C virus infection in active substance
users. Clin Infect Dis 2005, 40:S321–S324.
17. Mehta SH, et al: Limited uptake of hepatitis C treatment among injection
drug users. J Comm Health 2008, 33:126–133.
18. National Institute for Clinical Excellence: Technology Appraisal Guidance 75:
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment
of chronic HCV. London: National Institute for Clinical Excellence; 2004.
19. Reimer J, Backmund M, Haasen C: New psychiatric and psychological
aspects of diagnosis and treatment of hepatitis C and relevance for
opiate dependence. Curr Opin Psychiatr 2005, 18:678–683.
20. Topp L: 1 client, 2 needs: Improving access to hep C services. Substance
2007, 5:14–16.
21. Lazarus JV, Shete PB, Eramova I, Merkinaite S, Matic S: HIV/hepatitis
coinfection in eastern Europe and new pan-European approaches to
hepatitis prevention and management. Int J Drug Policy 2007, 18:426–432.
22. Lindenburg CEA, et al: Hepatitis C testing and treatment among active
drug users in Amsterdam: results from the DUTCH-C project. Eur J
Gastroenterol Hepatol 2011, 23:23–31.
23. Bobrova N, Sarang A, Stuikyte R, Lezhentsev K: Obstacles in provision of
anti-retroviral treatment to drug users in Central and Eastern Europe
and Central Asia: A regional overview. Int J Drug Policy 2007, 18:313–318.
24. Krusi A, Wood E, Montaner J, Kerr T: Social and structural determinants of
HAART access and adherence among injection drug users. Int J Drug
Policy 2010, 21:4–9.
25. Wolfe D, Carrieri MP, Shepard D: Treatment and care for injecting drug
users with HIV infection: a review of barriers and ways forward. Lancet
2010, 376.
26. Sarang A, Rhodes T, Sheon N: Systemic barriers to accessing HIV
treatment among people who inject drugs in Russia: a qualitative study.
Health Policy Plann 2012. in press.
27. Lally MA, Montstream-Quas SA, Tanaka S, Tedeschi SK, Morrow KM: A
qualitative study among injection drug using women in Rhode Island:
attitudes toward testing, treatment, and vaccination for hepatitis and
HIV. AIDS Patient Care STDS 2008, 22:53–64.
28. Treloar C, Rhodes T: The lived experience of hepatitis C and its treatment
among injecting drug users: qualitative synthesis. Qual Health Res 2009,
19:1321–1334.
29. John-Baptiste A, et al: Treatment of hepatitis C infection for current or former
substance abusers in a community setting. J Viral Hepat 2009, 16:557–567.
30. Rhodes T: Risk environments and drug harms: A social science for harm
reduction approach. Int J Drug Policy 2009, 20:193–201.
31. Harris M: Relapse to injecting drug use: A hepatitis C treatment concern.
Contemp Drug Probl 2009, 39:303–326.
32. Hopwood M, Treloar C: The experience of interferon-based treatments for
hepatitis C infection. Qual Health Res 2005, 15:635–646.
33. Sheppard K, Hubbert A: The patient experience of treatment for hepatitis
C. Gastroenterol Nursing 2006, 29:309–315.
34. Treloar C, Hopwood M: “Look, I’m fit, I’m positive and I’ll be all right,
thank you very much”: coping with hepatitis C treatment and unrealistic
optimism. Psychol Health Med 2008, 13:360–366.
35. Zickmund S, et al: Majority of patients with hepatitis C express physical,
mental, and social difficulties with antiviral treatment. Eur J Gastroenterol
Hepatol 2006, 18:381–388.
36. McNally S, Temple-Smith M: Now, later or never? Challenges associated
with hepatitis C treatment. Aust N Z J Public Health 2006, 30:422–427.
37. Schackman BR, Teixeira PA, Beeder AB: Offers of hepatitis C care do not
lead to treatment. J Urban Health 2007, 84:455–458.
38. Neale J: Homelessness, drug use and hepatitis C: a complex problem
explored within the context of social exclusion. Int J Drug Policy 2008,
19:429–435.
39. Treloar C, Newland J, Rance J, Hopwood M: Uptake and delivery of
hepatitis C treatment in opiate substitution treatment: perceptions of
clients and health professionals. J Viral Hep 2010, 17:839–844.
40. Swan D, et al: Barriers to and facilitators of hepatitis C testing,
management, and treatment among current and former injecting drug
users: a qualitative exploration. AIDS Patient Care STDS 2010, 24:753–762.
41. Coppola AG, et al: Hepatitis C knowledge among primary care residents: is
our teaching adequate for the times? Am J Gastroenterol 2004, 99:1720–1725.
42. Gupta L, Shah S, Ward JE: Educational and health service needs of
Australian general practitioners in managing hepatitis C. J Gastroenterol
Hepatol 2006, 21:694–699.
43. Treloar C, et al: Factors associated with hepatitis C knowledge among a
sample of treatment naive people who inject drugs. Drug Alcohol Depend
2011, 116:52–56.
44. Strauss S, et al: Barriers and facilitators to undergoing hepatitis C virus
(HCV) testing through drug treatment programs. J Drug Is 2008, 38:1161.
45. Harris M, Rhodes T, Martin A: Taming systems to create enabling
environments for HCV treatment: negotiating trust in the drug and
alcohol setting. Soc Sci Med 2013, 83:19–26.
46. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G: Patients’
experiences related to anti-viral treatment for hepatitis C. Patient Educ
Counsel 2006, 62:148–155.
47. Harris M: Injecting, infection, illness: abjection and hepatitis C stigma.
Body Soc 2009, 15:33–51.
48. Hopwood M, Treloar C, Bryant J: HCV and injecting-related discrimination
in New South Wales, Australia. Drugs Educ, Prev Policy 2006, 13:61–75.
49. Grebely J, et al: Factors associated with specialist assessment and
treatment for hepatitis C virus infection in New South Wales, Australia. J
Viral Hep 2011, 18:104–116.
50. Krook AL, Stokka D, Heger B, Nygaard E: Hepatitis C treatment of opioid
dependants receiving maintenance treatment: results of a Norwegian
pilot study. Eur Addict Res 2007, 13:216–221.
51. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ: Factors associated with
treatment failure of patients with psychiatric diseases and injecting drug
users in the treatment of genotype 2 or 3 hepatitis C chronic infection.
Liver Int 2009, 29:1051–1055.
52. Scott J, et al: Hepatitis C virus is infrequently evaluated and treated in an
urban HIV clinic population. AIDS Patient Care STDS 2009, 23:924–929.
53. Anand BS, et al: Alcohol use and treatment of hepatitis C virus: results of
a national multicenter study. Gastroenterology 2006, 130:1607–1616.
Harris and Rhodes Harm Reduction Journal 2013, 10:7 Page 9 of 11
http://www.harmreductionjournal.com/content/10/1/7
54. Gidding HF, et al: Predictors of deferral of treatment for hepatitis C
infection in Australian clinics. Med J Austr 2011, 194:398–402.
55. Dalgard O: Follow-Up Studies of Treatment for Hepatitis C Virus Infection
among Injection Drug Users. Clin Infect Dis 2005, 40:S336–S338.
56. Grebely J, et al: Reinfection with hepatitis C virus following sustained
virological response in injection drug users. JGastroenterol Hepatol 2010,
25:1281–1284.
57. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R: Hepatitis C virus
infection and injection drug users: Prevention, risk factors, and
treatment. Clin Infect Dis 2005, 40:S330–S335.
58. Backmund M, Meyer K, Edlin BR: Infrequent reinfection after successful
treatment for hepatitis C virus infection in injection drug users. Clin Infect
Dis 2004, 39:1540–1543.
59. Grebely J, et al: Treatment uptake and outcomes among current and
former injection drug users receiving directly observed therapy within a
multidisciplinary group model for the treatment of hepatitis C virus
infection. Int J Drug Policy 2007, 18:437–443.
60. Wilkinson M, et al: Community-based treatment for chronic hepatitis C in
drug users: high rates of compliance with therapy despite ongoing drug
use. Aliment Pharmacol Ther 2009, 29:29–37.
61. World Health Organisation Regional Office for Europe: Barriers and facilitators to
hepatitis C treatment for people who inject drugs: A qualitative study.
Copenhagen: World Health Organisation Regional Office for Europe; 2012.
62. Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG: Hepatitis C
treatment completion in individuals with psychiatric comorbidity and
depression. Gastroenterol Nursing 2011, 34:102–106.
63. Schaefer M, et al: Hepatitis C treatment in “difficult-to-treat” psychiatric
patients with pegylated interferon-alpha and ribavirin: response and
psychiatric side effects. Hepatology 2007, 46:991–998.
64. Murray MCM, et al: Hepatitis C virus treatment rates and outcomes in
HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. Eur J
Gastroenterol Hepatol 2011, 23:45–50.
65. Novick DM, Kreek MJ: Critical issues in the treatment of hepatitis C virus
infection in methadone maintenance patients. Addiction 2008, 103:905–918.
66. Taylor LE, et al: Treatment for hepatitis C virus genotype 1 infection in
HIV-infected individuals on methadone maintenance therapy. Drug Al
Depend 2011, 116:233–237.
67. Bova C, Ogawa LF, Sullivan-Bolyai S: Hepatitis C Treatment Experiences
and Decision Making Among Patients Living With HIV Infection. J Assoc
Nur AIDS Care 2010, 21:63–74.
68. Friedland G: Infectious disease comorbidities adversely affecting
substance users with HIV: Hepatitis C and tuberculosis. J Acquir Immune
Defic Syndr 2010, 55:S37–S42.
69. Khalsa JH, Vocci F: Clinical Management of Drug Addicts Infected with
Human Immunodeficiency Virus and Hepatitis C Virus. J Addict Dis 2008,
27:1–10.
70. Fischer B, Haydon E, Rehm J, Krajden M, Reimer J: Injection drug use and
the hepatitis C virus: Considerations for a targeted treatment approach -
The case study of Canada. J Urban Health-Bulletin New York Acad Med
2004, 81:428–447.
71. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated
with hepatitis C and interferon alpha: A review. Am J Psychiatr 2000,
157:867.
72. Edlin BR, et al: Overcoming Barriers to Prevention. Care, and Treatment of
Hepatitis C in Illicit Drug Users. Clin Infect Dis 2005, 40:S276–S285.
73. Day C, Ross J, Dolan K: Hepatitis C-related discrimination among heroin
users in Sydney: drug user or hepatitis C discrimination? Drug Al Rev
2003, 22:317–321.
74. Cullen W, Kelly Y, Stanley J, Langton D, Bury G: Experience of hepatitis C
among current or former heroin users attending general practice. Irish
Med J 2005, 98:73–74.
75. McGowan CE, Fried MW: Barriers to hepatitis C treatment. Liver Int 2012,
32:151–156.
76. Khaw F-M, Stobbart L, Murtagh MJ: ‘I just keep thinking I haven’t got it
because I’m not yellow’: a qualitative study of the factors that influence the
uptake of Hepatitis C testing by prisoners. BMC Public Health 2007, 7:98.
77. Temple-Smith M, et al: Gender differences in seeking care for hepatitis C
in Australia. J Substance Use 2007, 12:59–70.
78. Astell-Burt T, Flowerdew R, Boyle P, Dillon J: Does geographic access to
primary healthcare influence the detection of hepatitis C? Soc Sci Med
2011, 72:1472–1481.
79. Hopwood M, Nakamura T, Treloar C: Disclosing hepatitis C infection within
everyday contexts: Implications for accessing support and healthcare.
J Health Psychol 2010, 15:811–818.
80. Klitzman RL, et al: Intricacies and inter-relationships between HIV
disclosure and HAART: A qualitative study. AIDS Care 2004, 16:628–640.
81. Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH: Adherence in
antiretroviral therapy: A review of qualitative studies. AIDS 2007, 21:271–281.
82. Richmond J, Dunning P, Desmond P: Hepatitis C: A medical and social
diagnosis. Austr Nursing J 2004, 12:23–25.
83. Tindal C, Cook K, Foster N: Theorising stigma and the experiences of
injecting drug users in Australia. Austr J Primary Health 2010, 16:119–125.
84. Cheung RC, Hanson AK, Maganti K, Keeffe EB, Matsui SM: Viral hepatitis
and other infectious diseases in a homeless population. J Clin
Gastroenterol 2002, 34:476–480.
85. Hickman M, et al: Hepatitis C virus (HCV) prevalence, and injecting risk
behaviour in multiple sites in England in 2004. J Viral Hep 2007, 14:645–652.
86. Kim C, et al: Unstable housing and hepatitis C incidence among injection
drug users in a Canadian setting. BMC Public Health 2009, 9:270.
87. Stein JA, Nyamathi A: Correlates of hepatitis C virus infection in homeless
men: a latent variable approach. Drug Al Depend 2004, 75:89–95.
88. Cooper CL: Obstacles to successful HCV treatment in substance addicted
patients. J Addict Dis 2008, 27:61–68.
89. Grebely J, et al: Directly observed therapy for the treatment of hepatitis C
virus infection in current and former injection drug users. J Gastroenterol
Hepatol 2007, 22:1519–1525.
90. Central and Eastern European Harm Reduction Network: Hepatitis C among
injecting drug users in the new EU member states and neighboring countries:
situation, guidelines and recommendations. Lithuania: Central and Eastern
European Harm Reduction Network; 2007.
91. Monnet E, et al: Place of residence and distance to medical care
influence the diagnosis of hepatitis C: a population-based study. J
Hepatol 2006, 44:499–506.
92. Monnet E, et al: Socioeconomic context, distance to primary care and
detection of hepatitis C: a French population-based study. Soc Sci Med
2008, 66:1046–1056.
93. Harris KA, Arnsten JH, Litwin AH: Successful integration of hepatitis C
evaluation and treatment services with methadone maintenance.
J Addict Med 2010, 4:20–26.
94. Roux P, et al: The impact of methadone or buprenorphine treatment and
ongoing injection on highly active antiretroviral therapy (HAART)
adherence: evidence from the MANIF2000 cohort study. Addiction 2008,
103:1828–1836.
95. Uhlmann S, et al: Methadone maintenance therapy promotes initiation of
antiretroviral therapy among injection drug users. Addiction 2010,
105:907–913.
96. Batey RG, Jones T, McAllister C: Prisons and HCV: a review and a report on an
experience in New South Wales Australia. Int J Prisoner Health 2008, 4:156–163.
97. Hunt DR, Saab S: Viral hepatitis in incarcerated adults: a medical and
public health concern. Am J Gastroenterol 2009, 104:1024–1031.
98. Remy AJ, et al: Treatment for hepatitis C in jailhouses is doable and
successful: definitive data of first national French study (POPHEC). Heroin
Addiction Related Clin Prob 2006, 8:47–49.
99. Brunsden A: Hepatitis C in prisons: evolving toward decency through
adequate medical care and public health reform. UCLA Law Rev 2006,
54:465–507.
100. Farley J, et al: Feasibility and outcome of HCV treatment in a Canadian
federal prison population. Am J Public Health 2005, 95:1737–1739.
101. Van Thiel DH, Anantharaju A, Creech S: Response to treatment of hepatitis
C in individuals with a recent history of intravenous drug abuse. Am J
Gastroenterol 2003, 98:2281–2288.
102. Brener L, Von Hippel W, Kippax S: Prejudice among health care workers
toward IDUs with hepatitis C: does greater contact lead to less
prejudice? Int J Drug Policy 2007, 18:381–387.
103. Paterson BL, Backmund M, Hirsch G, Yim C: The depiction of stigmatization in
research about hepatitis C. Int J Drug Policy 2007, 18:364–373.
104. Hopwood M, Treloar C: The drugs that dare not speak their name:
injecting and other illicit drug use during treatment for hepatitis C
infection. Int J Drug Policy 2007, 18:374–380.
105. Treloar C, Newland J, Harris M, Deacon R, Maher L: A diagnosis of hepatitis
C - insights from a study on patient’s experiences. Austr Family Phys 2010,
39:589–592.
Harris and Rhodes Harm Reduction Journal 2013, 10:7 Page 10 of 11
http://www.harmreductionjournal.com/content/10/1/7
106. Giordano C, Druyts E, Garber G, Cooper C: Evaluation of immigration
status, race and language barriers on chronic HCV infection
management and treatment outcomes. Eur J Gastroenterol Hepatol 2009,
21:963.
107. Gifford S, O’Brien M, Bammer G, Banwell C, Stoove M: Australian women’s
experiences of living with hepatitis C virus: results from a cross-sectional
survey. Eur J Gastroenterol Hepatol 2003, 18:841–850.
108. Broers B, et al: Barriers to interferon-alpha therapy are higher in
intravenous drug users than in other patients with acute hepatitis C. J
Hepatol 2005, 42:323–328.
109. Khokhar OS, Lewis JH: Reasons why patients infected with chronic
hepatitis C virus choose to defer treatment: do they alter their decision
with time? Digestive Dis Sci 2007, 52:1168–1176.
110. Lowry DJ, Ryan JD, Ullah N, Kelleher TB, Crowe J: Hepatitis C management:
the challenge of dropout associated with male sex and injection drug
use. Eur J Gastroenterol Hepatol 2011, 23:32–40.
111. Campbell N: Using women: Gender, drug policy and social justice. New York,
London: Routledge; 2000.
112. Kurtz SP, Surratt HL, Kiley MC, Inciardi JA: Barriers to health and social
services for street-based sex workers. J Health Care Poor Underserved 2005,
16:345–361.
113. Bourgois P, Prince B, Moss A: The everyday violence of hepatitis C among
young women who inject drugs in San Francisco. Hum Organ 2004,
63:253.
114. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR: Hepatitis C virus
infection in San Francisco’s HIV-infected urban poor. J Gen Int Med 2004,
19:357–365.
115. Almasio PL, et al: Recommendations for the prevention, diagnosis, and
treatment of chronic hepatitis b and c in special population groups
(migrants, intravenous drug users and prison inmates). Digest Liver Dis
2011, 43:589–595.
116. World Health Organisation, UN Office of Drugs and Crime & UNAIDS:
Technical guide for countries to set targets for universal access to HIV
prevention, treatment and care for injecting drug users. Geneva: World Health
Organisation, UN Office of Drugs and Crime & UNAIDS; 2009.
117. Litwin AH, et al: Successful treatment of chronic hepatitis C with
pegylated interferon in combination with ribavirin in a methadone
maintenance treatment program. J Subs Abuse Treat 2009, 37:32–40.
118. Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an
interim analysis. Drug Alcohol Depend 2002, 67:117–123.
119. Zanini B, Lanzini A: Antiviral treatment for chronic hepatitis C in illicit
drug users: a systematic review. Antiviral Ther 2009, 14:467–479.
120. Hagan H, Pouget E, Des Jarlais D: A systematic review and meta-analysis
of interventions to prevent hepatitis C virus infection in people who
inject drugs. J Infect Dis 2011, 204:74–83.
121. Turner K, et al: The impact of needle and syringe provision and opiate
substitution therapy on the incidence of hepatitis C virus in injecting
drug users: pooling of UK evidence. Addiction 2011, 106:1978–1988.
122. Harris M, Rhodes T: Methadone diversion as a protective strategy: the
harm reduction potential of ‘generous constraints’. Int J Drug Policy 2013.
http://www.ncbi.nlm.nih.gov/pubmed/23199896.
123. Moussalli J, et al: Factors to improve the management of hepatitis C in
drug users: an observational study in an addiction centre. Gastroenterol
Res Pract 2010:4. http://www.ncbi.nlm.nih.gov/pubmed/20811482.
124. Cournot M, et al: Management of hepatitis C in active drugs users:
experience of an addiction care hepatology unit. Gastroenterol Clin Biol
2004, 28:533–539.
125. Mason S, Watts A, Sheils S, Koorey D: Improving access to HCV treatment:
external jugular venepuncture can overcome problems with difficult
venous access. Int J Drug Policy 2007, 18:433–436.
126. Hallinan R, Byrne A, Dore G: Harm reduction, hepatitis C and opioid
pharmacotherapy: an opportunity for integrated hepatitis C virus-
specific harm reduction. Drug Al Rev 2007, 26:437–443.
127. Sylvestre D, Zweben J: Integrating HCV services for drug users: a model to
improve engagement and outcomes. Int J Drug Policy 2007, 18:406–410.
128. Strauss S, Munoz-Plaza C, Rosedale M, Rindskopf D, Lunievicz J: Enhancing
drug treatment program staff’s self-efficacy to support patients’ HCV
needs. J Soc Work Prac Addict 2011, 11:254–269.
129. Arora A, et al: Outcomes of treatment for hepatitis C virus infection by
primary care providers. New England J Med 2011, 364(2199):2199–2207.
130. Grebely J, et al: Optimizing assessment and treatment for hepatitis C
virus infection in illicit drug users: a novel model incorporating
multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010,
22:270–277.
131. Norman J, et al: The acceptability and feasibility of peer worker support
role in community based HCV treatment for injecting drug users. Harm
Red J 2008, 5:5.
132. Rance J, Newland J, Hopwood M, Treloar C: The politics of place(ment):
problematising the provision of hepatitis C treatment within opiate
substitution clinics. Soc Sci Med 2012, 74:245–253.
133. Treloar CJ, Fraser SM: Hepatitis C treatment in pharmacotherapy services:
increasing treatment uptake needs a critical view. Drug Al Rev 2009,
28:436–440.
134. Brener L, Treloar C: Alcohol and other drug treatment experiences of
hepatitis C-positive and negative clients: implications for hepatitis C
treatment. Aust Health Rev 2009, 33:100–106.
135. Strathdee SA, et al: HIV and risk environment for injecting drug users: the
past, present, and future. Lancet 2010, 376:268–284.
doi:10.1186/1477-7517-10-7
Cite this article as: Harris and Rhodes: Hepatitis C treatment access and
uptake for people who inject drugs: a review mapping the role of social
factors. Harm Reduction Journal 2013 10:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Harris and Rhodes Harm Reduction Journal 2013, 10:7 Page 11 of 11
http://www.harmreductionjournal.com/content/10/1/7
